Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-04-26
2011-04-26
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07932287
ABSTRACT:
The invention provides compositions for and methods of treating a number of disorders. In one embodiment, the invention provides a method of treating a wide range of conditions by administering to a human being in need of such treatment, a therapeutically effective amount of (a) N-6-trimethyl-L-lysine of at least 98% purity, (b) a prodrug thereof, (c) an aliphatic chain derivative thereof, (d) an ester derivative thereof, (e) an amide derivative thereof, or (f) a pharmaceutically acceptable salt of said N-6-trimethyl-L-lysine or said prodrug.
REFERENCES:
patent: 7256002 (2007-08-01), Cox et al.
patent: 2006207 (1979-05-01), None
Aguado, B., et al., Biochem. J., vol. 341, pp. 679-689,1999.
Angelino, F., et al., Int. J. Clin. Pharmacol. Ther. Toxicol., vol. 23, No. 10, pp. 569-572, 1985.
Balch, Phyllis A., et al, “Prescription For Nutritional Healing, 3rd edition”, Avery Publishing, p. 47, New York, 2000.
Barisic N., et al., Croatian Medical Journal, vol. 44, No. 4, pp. 489-493, 2003.
Barrett, G.C., “Amino Acid Derivatives, A Practical Approach”, Oxford University Press, 1999.
Brass, E.P., et al., J. Am. Coll. Nutr., vol. 17, No. 3, pp. 207-215, 1998.
Broom, M.F., et al., European Journal of Paediatric Neurology. 5 Suppl A, pp. 33-35, 2001.
Chattopadhyay, S., et al., Human Molecular Genetics. vol. 11, No. 12, pp. 1421-1431, 2002.
Cherchi, A., et al., Int. J. Clin. Pharmacol. Ther. Toxicol., vol. 23, No. 10, pp. 569-572, 1985.
Das, A M., et al., European Journal of Paediatric Neurology, 5 Suppl A, pp. 143-146, 2001.
Davis, A. T., et al., Chromatogr, vol. 306, pp. 79-87, 1984.
De Voer, G., et al., European Journal of Paediatric Neurology, 5 Suppl A, pp. 115-120, 2001.
Doqu, K.oqi, National Kidney Foundation, Am. J. Kidney Dis., vol. 35, No. 6 Suppl 2 S1, p. 140 , 2000.
Dunn, W.A., et al., J.Biol. Chem. vol. 257, pp. 7948-7951, 1982.
Dunn, W.A., et al., J. Biol. Chem. vol. 259, pp. 10764-10770, 1984.
Eriksson, B.O., et al., Eur.J. Pediatr., vol. 147, pp. 662-663, 1988.
“Escherichia coliandSalmonella”, Cellular and Molecular Biology, 2nd Edition, American Society for Microbiology, Washington, D.C., 1996.
Ezaki, J., et al., J Biochem (tokyo) Sep., vol. 128, No. 3, pp. 509,2000.
Ghose, M., et al., Pharm. Res., vol. 8, pp. 771-775, 1009.
Girgis, S., et al., Gene vol. 210, pp. 315-324, 1998.
Gupta, P., et al., P.N.A.S.USA, vol. 98, No. 24, p. 13571, 2001.
Gupta, P., et al., Molecular Psychiatry, vol. 7, pp. 434-436, 2002.
Gupta, P., et al., P.N.A.S. USA., vol. 100, No. 21m, pp. 12325-12330, 2003.
Hagen, TM, et al., Proc. Natl. Acad. Sci.USA., vol. 95, No. 16, pp. 9562-9566,1998.
Vesa, J., et al., Nature, vol. 376, pp. 584-587,1995.
Hellsten, E., et al., Nature vol. 15, pp. 5240-5245, 1996.
Higuchi, T., et al., Prodrugs as Novel Delivery Systems, vol. 14 of the ACS Symposium Series.
Higuchi, T., et al., “Bioreverible Carriers in Drug Design”, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Hofmann, S.L., et al., Current Molecular Medicine. vol. 2, No. 5, pp. 423-437, 2002.
Hulse, J.D., et al., Fed. Proc. Fed.Am. Soc.Exp. Biol., vol. 38, p. 676, 1979.
Isosomppi, J., et al., Human Molecular Genetics. vol. 11, No. 8, pp. 885-891, 2002.
Iyer, R.N., et al., J Assoc Physicians India, vol. 8, No. 11, pp. 1050-1052, 2000.
Jones, John, “Amino Acids and Peptide Synthesis”, Oxford University Press, 1992.
Kakimoto, Y., et al., J. Biol. Chem. vol. 245, pp. 5751-5758, 1970.
Karpati, G., et al., Neurology, vol. 25, pp. 16-24, 1975.
Katz, M.L., et al., European Journal of Paediatric Neurology. 5 Suppl A, pp. 109-114, 2001.
M.L. Kaz, M.L., Biochem.Biophy. Acta, vol. 1317, pp. 192-198,1996.
Labadie, J., et al., N. N. Biochem. J., vol. 160, pp. 85-95, 1976.
Lam CW., et al., American Journal of Medical Genetics, vol. 99, No. 2, pp. 161-163, 2001.
Lavrov, A.Y., et al., European Journal of Paediatric Neurology, vol. 6, No. 3, pp. 161-164, 2002.
Lehtovirta, Maarit, et al., Human Molecular Genetics,vol. 10, No. 1, 2001.
Lehtovirta, Maarit, et al., Human Molecular Genetics,vol. 10, No. 1, pp. 69-75, 2001.
Lindblad, B., et al., J. Am. Chem. Soc., vol. 91, pp. 4604-4606, 1969.
Lonnqvist, T., et al., Neurology, vol. 57, No. 8, pp. 1411-1416, 2001.
Mao, Q., et al., FEBS Letters, vol. 555, No. 2, pp. 351-357, 2003.
Martin, J.-J., Dev. Neurosci. vol. 13, pp. 331-338, 1991.
Mitchell, W.A., et al., European Journal of Paediatric Neurology, 5 Suppl A, pp. 121-125, 2001.
Mitchell, W.A., et. al., European Journal of Paediatric Neurology, 5 Suppl A, pp. 21-27, 2001.
Mitchison, H.M., et al., Brain Pathology, vol. 14, No. 1, pp. 86-96, 2004.
Moretti, S., et al., “Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis”, a pilot study, Blood, vol. 91, No. 10, pp. 3817-3824,1998.
Muller, VJ., et al., European Journal of Paediatric Neurology, 5 Suppl A, pp. 197-201, 2001.
Nijssen, P.C., et al., Movement Disorders, vol. 17, No. 3, pp. 482-487, 2002.
Ninds Batten Disease Information Page at http://www.ninds.nih.gov/disorders/batten/batten.htm.
Nucleic Acids Res. vol. 30, No. 1, p. 59, 2002.
O'Connor, JE, Adv Exp Med Biol., vol. 272, pp. 183-195, 1990.
Ogawa, H., et al., J. Biochem.(Tokyo), vol. 90, pp. 381-390, 1981.
Olson, et al., J. Nutr. vol. 117, No. 6, pp. 1024-1031, 1987.
Persaud-Sawin, D.A., et al., Human Molecular Genetics. vol. II, No. 18, pp. 2129-2142, 2002.
Rakheja D., et al., Biochemical & Biophysical Research Communications, vol. 317, No. 4, pp. 988-991, 2004.
Rebouche, C.J., et al., Biochim. Biophys. Acta, pp. 22-29, 1980.
Sachan, D.S., et al., Biochem, J., vol. 188, pp. 529-534, 1980.
Sandor, A., et al., Clin. Chim. Acta., vol. 176, pp. 17-27,1988.
Santavuori, P., et al., European Journal of Paediatric Neurology, 5 Suppl A, pp. 157-161, 2001.
Sappington, R.M., et al., Investigative Ophthalmology & Visual Science, vol. 44, No. 9, 3725-3731, 2003.
Savukoski, M., et al., Nat.Genet, vol. 19, pp. 286-288,1998.
Scholte, H.R., et al., J.Clin. Chem..Clin. Biochem. vol. 28, pp. 351-357, 1990.
Scholte, HR, J Clin Chem Clin Biochem, vol. 28, No. 5, p. 35, May 1990.
Sharp, J.D., et al., Hum. Mol.Genet., vol., 6, pp. 591-595,1997.
Sharp, J.D., et al., European Journal of Paediatric Neurology. 5 Suppl A, pp. 29-31, 2001.
Siakotos, A.N., et al., European Journal of Paediatric Neurology. 5 Suppl A, pp. 151-156, 2001.
Sleat, D.E., et al., Science, vol. 277, pp. 1802-1805, 1997.
Sondhi, D., et al., Archives of Neurology, vol. 58, No. 11, pp. 1793-1798, 2001.
Stanley, C.A., et al., Ann.Neuro. vol. 30, pp. 709-716, 1991.
Tein, I., J Child Neurol, vol. 17, Suppl No. 3, 3S57-82; discussion 3S82-3, Dec. 2002.
Teixeira, C.A., et al., Human Mutation, vol. 21, No. 5, pp. 502-508, 2003.
Treem, W.R., et al., N.EngI.J.Med, vol. 319, pp. 1331-1336, 1988.
Van Diggelen, O.P., et al., Annals of Neurology, vol. 50, No. 2, pp. 269-272, 2001.
Vaz, Frederic M., et al., Clin. Chem. vol. 48, No. 6, pp. 826-834, 2002.
Vaz, F.M., et al., Biochem.J., vol. 361, pp. 417-429, 2002.
Wang, Y., et al., PRoc. Natl.Acad. Sci. USA vol. 96, pp. 2356-2360, 1999.
Warburton, M.J., et al., FEBS Letters, vol. 500, No. 3, pp. 145-148, 2001.
Weimer, J.M., et al., NeuroMolecular Medicine. vol. 1, No. 2, pp. 111-124, 2002.
Weissman, N., et al. J.Biol.Chem. vol. 140, p. 549, 1943.
Wang, Y., et al., Proc. Natl.Acad. Sci. USA, vol. 96, pp. 2356-2360, 1999.
Winter, S., et al., J. Child Neurol, vol. 10, Supple No. 2, pp. 45-51, 1995.
Srivastav Sant K.
Srivastava Suresh C.
Szymanski, Jr. Stanley J.
Chemgenes Corporation
Law Offices of Indu M. Anand
Szymanski, Jr. Stanley J.
Weddington Kevin
LandOfFree
Therapeutic compositions and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630660